OGN vs. GSK
Compare and contrast key facts about Organon & Co. (OGN) and GlaxoSmithKline plc (GSK).
Scroll down to visually compare performance, riskiness, drawdowns, and other indicators and decide which better suits your portfolio: OGN or GSK.
Performance
OGN vs. GSK - Performance Comparison
Returns By Period
In the year-to-date period, OGN achieves a 11.25% return, which is significantly higher than GSK's -5.50% return.
OGN
11.25%
-12.73%
-28.41%
41.84%
N/A
N/A
GSK
-5.50%
-11.61%
-22.86%
-0.51%
4.00%
4.97%
Fundamentals
| OGN | GSK | |
|---|---|---|
| Market Cap | $4.01B | $68.74B |
| EPS | $5.05 | $1.54 |
| PE Ratio | 3.09 | 21.88 |
| Total Revenue (TTM) | $6.41B | $31.27B |
| Gross Profit (TTM) | $3.73B | $22.46B |
| EBITDA (TTM) | $1.69B | $7.73B |
Key characteristics
| OGN | GSK | |
|---|---|---|
| Sharpe Ratio | 1.16 | 0.08 |
| Sortino Ratio | 1.88 | 0.26 |
| Omega Ratio | 1.23 | 1.03 |
| Calmar Ratio | 0.67 | 0.07 |
| Martin Ratio | 4.24 | 0.18 |
| Ulcer Index | 10.96% | 9.42% |
| Daily Std Dev | 39.92% | 21.58% |
| Max Drawdown | -69.56% | -54.70% |
| Current Drawdown | -55.41% | -24.87% |
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Correlation
The correlation between OGN and GSK is 0.29, which is considered to be low. This implies their price changes are not closely related. A low correlation is generally favorable for portfolio diversification, as it helps to reduce overall risk by spreading it across multiple assets with different performance patterns.
Risk-Adjusted Performance
OGN vs. GSK - Risk-Adjusted Performance Comparison
This table presents a comparison of risk-adjusted performance metrics for Organon & Co. (OGN) and GlaxoSmithKline plc (GSK). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.
Dividends
OGN vs. GSK - Dividend Comparison
OGN's dividend yield for the trailing twelve months is around 7.42%, more than GSK's 4.62% yield.
| TTM | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
OGN Organon & Co. | 7.42% | 7.77% | 4.01% | 1.84% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
GSK GlaxoSmithKline plc | 4.62% | 3.75% | 4.78% | 6.14% | 6.86% | 5.34% | 6.93% | 7.13% | 8.82% | 7.43% | 7.60% | 5.53% |
Drawdowns
OGN vs. GSK - Drawdown Comparison
The maximum OGN drawdown since its inception was -69.56%, which is greater than GSK's maximum drawdown of -54.70%. Use the drawdown chart below to compare losses from any high point for OGN and GSK. For additional features, visit the drawdowns tool.
Volatility
OGN vs. GSK - Volatility Comparison
Organon & Co. (OGN) has a higher volatility of 11.18% compared to GlaxoSmithKline plc (GSK) at 6.23%. This indicates that OGN's price experiences larger fluctuations and is considered to be riskier than GSK based on this measure. The chart below showcases a comparison of their rolling one-month volatility.
Financials
OGN vs. GSK - Financials Comparison
This section allows you to compare key financial metrics between Organon & Co. and GlaxoSmithKline plc. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.
Total Revenue: Total amount of money received from sales and other business activities